Genmab AS (GMAB)vsBeiGene, Ltd. (ONC)
GMAB
Genmab AS
$26.11
+1.16%
HEALTHCARE · Cap: $15.94B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 44% more annual revenue ($5.34B vs $3.72B). GMAB leads profitability with a 25.9% profit margin vs 5.4%. GMAB trades at a lower P/E of 16.8x. GMAB earns a higher WallStSmart Score of 54/100 (C-).
GMAB
Buy54
out of 100
Grade: C-
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-187.1%
Fair Value
$10.47
Current Price
$26.11
$15.64 premium
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 26 of every $100 in revenue as profit
Attractively priced relative to earnings
Strong operational efficiency at 23.0%
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
3.0% revenue growth
Weak financial health signals
Earnings declined 94.4%
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Price/Book, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 25.9% and operating margin at 23.0%.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
GMAB profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.75 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
GMAB generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
GMAB scores higher overall (54/100 vs 42/100), backed by strong 25.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?